If successful, this could challenge existing oral GLP-1 offerings and expand patient choice by eliminating injections
Urinary losses of carnitine via this route can be 10-fold greater than the sum of daily carnitine intake and biosynthesis and lead to systemic carnitine depletion (see Drug interactions) (39)
Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer
Unlike many existing GLP-1 receptor agonists, orforglipron can be taken any time of day without food or water restrictions, offering greater convenience for patients
Oral erythromycin and symptomatic relief of gastroparesis: A systematic review
Current evidence does not establish a causal link between GLP-1 medicines and increased overall cancer risk in humans